SCN9A
SCN9A encodes the pore-forming alpha subunit of Nav1.7, a voltage-gated sodium channel that helps drive the depolarizing phase of action potentials. Also known as PN1, NE-NA, NENA and ETHA, it has a central role in nociception and the sensory perception of pain. Browse Assay Genie's current range of SCN9A research reagents below, or read on for the biology behind the target.
SCN9A is the pore-forming subunit of Nav1.7, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Nav channels, also called VGSCs or VDSCs, switch between closed and open conformations depending on the voltage difference across the membrane. In the open state they allow Na(+) ions to pass selectively through the pore along their electrochemical gradient. The resulting influx of Na(+) depolarizes the membrane and initiates the propagation of electrical signals throughout cells and tissues.
Nav1.7 plays a crucial role in controlling excitability and action potential propagation in nociceptor neurons, and so contributes to the sensory perception of pain. The SCN9A protein is found at the cell membrane and in neuron projections, including axons. It belongs to the sodium channel family (TC 1.A.1.10), in the Nav1.7/SCN9A subfamily, and HGNC places the gene in the group of sodium voltage-gated channel alpha subunits. Mouse and rat both have an orthologous Scn9a gene.
The SCN9A gene was previously named sodium channel, voltage-gated, type IX, alpha polypeptide (or alpha subunit). According to the NCBI Gene summary, it plays a significant role in nociception signalling, and mutations in it have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain and paroxysmal extreme pain disorder. This makes Nav1.7 a frequent subject in studies of pain biology and channelopathies.
Nav1.7 controls excitability and action potential propagation in nociceptor neurons, making it central to studies of how pain is sensed.
SCN9A mutations are associated with primary erythermalgia, channelopathy-associated insensitivity to pain and paroxysmal extreme pain disorder.
As a voltage-gated sodium channel, Nav1.7 mediates the depolarizing phase of action potentials in excitable membranes.
Nav1.7 switches between closed and open conformations with membrane voltage, providing a model for selective Na(+) permeation and electrical signalling.
SCN9A encodes the pore-forming subunit of the Nav1.7 sodium channel. When open, the channel lets Na(+) ions enter along their electrochemical gradient, depolarizing the membrane and driving action potentials. In nociceptor neurons this controls excitability and signal propagation, contributing to the sensory perception of pain.
SCN9A is also called Nav1.7, PN1, NE-NA, NENA and ETHA. Its UniProt name is sodium channel protein type 9 subunit alpha, and earlier HGNC names described it as sodium channel, voltage-gated, type IX, alpha polypeptide or alpha subunit.
Mutations in SCN9A have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain and paroxysmal extreme pain disorder. Mouse and rat each carry an orthologous gene named Scn9a; check the datasheet of any product for its validated reactivity.
Other sodium channel subunits and related ion channel targets with research products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q15858; product specifications from Assay Genie datasheets.